Fatal cardiomyopathy associated with pegylated interferon/ribavirin in a patient with chronic hepatitis C

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 3, 2006, Pages 287-289

  Condat, Bertrand ^a,b   Asselah, Tarik ^b   Zanditenas, David ^a   Estampes, Bertrande ^a   Cohen, Ariel ^c   O'Toole, Dermot ^b   Bonnet, Joëlle ^a   Ngo, Yann ^a   Marcellin, Patrick ^b   Blazquez, Martine ^a  

^a Hopital Saint Camille   (France)

^b BEAUJON HOSPITAL   (France)

^c HÔPITAL SAINT ANTOINE   (France)

Author keywords

Cardiomyopathy; Chronic hepatitis C; Myocarditis; Pegylated interferon; Ribavirin

Indexed keywords

PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; CARDIOLOGIST; CARDIOMEGALY; CARDIOMYOPATHY; CARDIOTOXICITY; CASE REPORT; CONGESTIVE CARDIOMYOPATHY; CONSULTATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; DYSPNEA; FATIGUE; HEART PALPITATION; HEPATITIS C; HUMAN; HYPOKINESIA; MALE; NEUTROPENIA; PRIORITY JOURNAL; PROBABILITY; SIDE EFFECT; SYMPTOM; TREATMENT RESPONSE; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; CARDIOMYOPATHY, DILATED; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FATAL OUTCOME; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 33644590228     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200603000-00010     Document Type: Article

References (16)

1. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339:900-905.
2. Kuwata A, Ohashi M, Sugiyama M, Ueda R, Dohi Y. A case of reversible dilated cardiomyopathy after alpha-interferon therapy in a patient with renal cell carcinoma. Am J Med 2002; 324:331-334.
3. Uehara E, Uesugi T, Tasaka T, Matsuhashi Y, Tamura T, Kuwajima M, et al. Reversible cardiomyopathy secondary to interferon-alpha in chronic myelogenous leukemia. Gan To Kagaku Ryoho 2002; 29:317-321.
4. Morino Y, Hara K, Ushikoshi H, Tanabe K, Kuroda Y, Noguchi T, et al. Gamma-interferon-induced cardiomyopathy during treatment of renal cell carcinoma: a case report. J Cardiol 2000; 36:49-57.
5. Matsumori A. Hepatitis C virus and cardiomyopathy. Herz 2000; 25:249-254.
6. Angulo MP, Navajas A, Galdeano JM, Astigarraga I, Fernandez-Teijeiro A. Reversible cardiomyopathy secondary to alpha-interferon in an infant. Pediatr Cardiol 1999; 20:293-294.
7. Teragawa H, Hondo T, Amano H, Hino F, Ohbayashi M. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart J 1996; 37:905-915.
8. Kruit WH, Punt KJ, Goey SH, de Mulder PH, van Hoogenhuyze DC, Henzen-Logmans SC, et al. Cardiotoxicity as a dose-limiting factor in a schedule of high dose bolus therapy with interleukin-2 and alpha-interferon. An unexpectedly frequent complication. Cancer 1994; 74:2850-2856.
9. Zimmerman S, Adkins D, Graham M, Petruska P, Bowers C, Vrahnos D, et al. Irreversible, severe congestive cardiomyopathy occurring in association with interferon alpha therapy. Cancer Biother 1994; 9: 291-299.
10. Guillot P, Barbuat C, Richard B, Jourdan J. Reversible cardiomyopathy induced by interferon. Therapie 1993; 48:65-66.
11. Kura N, Kojima S, Kakehi R, Yokoyama H, Fujiwara T, Gotoh S. Dilated cardiomyopathy following alpha interferon therapy of renal tumor with pulmonary metastases: a case report. Hinyokika Kiyo 1992; 38:1051-1054.
12. Azar JJ, Rheriault RL. Acute cardiomyopathy as a consequence of treatment with interleukin-2 and interferon-alpha in a patient with metastatic carcinoma of the breast. Am J Clin Oncol 1991; 14:530-533.
13. Cohen MC, Huberman MS, Nesto RW. Interferon alfa-induced cardiac dysfunction. N Engl J Med 1990; 322:1469.
14. Sonnenblick M, Rosenmann D, Rosin A. Reversible cardiomyopathy induced by interferon. BMJ 1990; 300:1174-1175.
15. Deyton LR, Walker RE, Kovacs JA, Herpin B, Parker M, Masur H, et al. Reversible cardiac dysfunction associated with interferon alfa therapy in AIDS patients with Kaposi's sarcoma. N Engl J Med 1989; 321: 1246-1249.
16. Cohen MC, Huberman MS, Nesto RW. Recombinant alpha 2 interferon-related cardiomyopathy. Am J Med 1988; 85:549-551.